Recombinant Human NRG1-beta 1/HRG1-beta 1 ECD Protein

Carrier Free

Catalog # Availability Size / Price Qty
377-HB-050/CF

With Carrier

Catalog # Availability Size / Price Qty
377-HB-050
Recombinant Human NRG1-beta 1/HRG1-beta 1 ECD Protein Bioactivity
2 Images
Product Details
Citations (14)
FAQs
Reviews (4)

Recombinant Human NRG1-beta 1/HRG1-beta 1 ECD Protein Summary

Product Specifications

Purity
>90%, by SDS-PAGE under reducing conditions and visualized by silver stain
Endotoxin Level
<0.10 EU per 1 μg of the protein by the LAL method.
Activity
Measured in a serum-free cell proliferation assay using MCF‑7 human breast cancer cells. Karey, K.P. et al. (1988) Cancer Research 48:4083. The ED50 for this effect is 2.5-12.5 ng/mL.
Source
E. coli-derived human Neuregulin-1 beta 1/NRG1 beta 1 protein
Ser2-Lys246
Accession #
N-terminal Sequence
Analysis
Ser2
Predicted Molecular Mass
26.9 kDa

Product Datasheets

You must select a language.

x

377-HB (with carrier)

You must select a language.

x

377-HB/CF (carrier free)

Carrier Free

What does CF mean?

CF stands for Carrier Free (CF). We typically add Bovine Serum Albumin (BSA) as a carrier protein to our recombinant proteins. Adding a carrier protein enhances protein stability, increases shelf-life, and allows the recombinant protein to be stored at a more dilute concentration. The carrier free version does not contain BSA.

What formulation is right for me?

In general, we advise purchasing the recombinant protein with BSA for use in cell or tissue culture, or as an ELISA standard. In contrast, the carrier free protein is recommended for applications, in which the presence of BSA could interfere.

377-HB

Formulation Lyophilized from a 0.2 μm filtered solution in Acetonitrile and TFA with BSA as a carrier protein.
Reconstitution Reconstitute at 100 μg/mL in sterile PBS containing at least 0.1% human or bovine serum albumin.
Shipping The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, -20 to -70 °C under sterile conditions after reconstitution.

377-HB/CF

Formulation Lyophilized from a 0.2 μm filtered solution in Acetonitrile and TFA.
Reconstitution Reconstitute at 100 μg/mL in sterile PBS.
Shipping The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, -20 to -70 °C under sterile conditions after reconstitution.

Scientific Data

Bioactivity Recombinant Human NRG1-beta 1/HRG1-beta 1 ECD Protein Bioactivity View Larger

Recombinant Human NRG1-beta 1/HRG1-beta 1 Extracellular Domain (Catalog # 377-HB) stimulates cell proliferation of the MCF-7 human breast cancer cell line in a serum free assay. The ED50 for this effect is 2.5-12.5 ng/mL.

SDS-PAGE Recombinant Human NRG1-beta 1/HRG1-beta 1 ECD Protein SDS-PAGE View Larger

1 μg/lane of Recombinant Human NRG1-beta 1/HRG1-beta 1 Extracellular Domain (Catalog # 377-HB) was resolved with SDS-PAGE under reducing (R) conditions and visualized by silver staining, showing a single band at 36 kDa.

Background: Neuregulin-1 beta 1/NRG1 beta 1

The Neuregulin family of structurally related glycoproteins comprises products from four distinct but related genes, Nrg-1, Nrg-2, Nrg-3, and Nrg-4. Through alternative splicing or the use of alternative promoters, Nrg-1 has been shown to encode more than 14 soluble or transmembrane proteins. The extracellular domain of the transmembrane NRG1 isoforms can be proteolytically cleaved to release soluble growth factors. All NRG1 isoforms contain an EGF-like domain ( alpha - or beta -splice variant that differ in their C-terminal region) that is required for their direct binding to the ErbB3 or ErbB4 receptor tyrosine kinases. The ErbB3 or ErbB4 subsequently recruits and heterodimerizes with ErbB2, resulting in tyrosine phosphorylation and NRG1 signaling. NRG1 isoforms can be classified into three major subtypes. Type I (Neu Differentiation Factor, NDF; Heregulin, HRG; Acetylcholine Receptor Inducing Activity, ARIA) and type II (Glial Growth Factor, GGF) NRG1s have an immunoglobulin (Ig)-like domain N-terminal to the EGF-like domain. Type I NRG1s differ from type II NRG1s by having a glycosylation-rich domain between the Ig-like and the EGF-like domains. Type III NRG1s (Sensory and Motor neuron-Derived Factor) lacks the Ig-like domain but has a cysteine rich domain (CRD) instead. NRG1 isoforms show distinct spatial and temporal expression patterns. These proteins play important roles during development of both the nervous system and the heart. They have been shown to regulate the selective expression of neurotransmitter receptors in neurons and at the neuromuscular junction, and promote the differentiation and development of Schwann cells from neural crest stem cells. NRG1s have also been shown to be involved in the establishment of the oligodendroglial lineage.

References
  1. Buonanno, A., and G.D Fischbach (2001) Curr. Opin. Neurobiol. 11:287.
  2. Adlkofer, K. and C. Lai (2000) Glia 29:104.
  3. Garratt, A.N. et al., (2000) BioEssays 22:987.
Entrez Gene IDs
3084 (Human); 211323 (Mouse); 112400 (Rat)
Alternate Names
ARIA; GGF; GGF2; HGL; HRG; HRG1; HRGA; MST131; MSTP131; NDF; neuregulin 1; Neuregulin1 beta 1; Neuregulin-1 beta 1; NRG1-IT2; SMDF

Citations for Recombinant Human NRG1-beta 1/HRG1-beta 1 ECD Protein

R&D Systems personnel manually curate a database that contains references using R&D Systems products. The data collected includes not only links to publications in PubMed, but also provides information about sample types, species, and experimental conditions.

14 Citations: Showing 1 - 10
Filter your results:

Filter by:

  1. Activation of mTORC1 and c-Jun by Prohibitin1 loss in Schwann cells may link mitochondrial dysfunction to demyelination
    Authors: G Della-Flor, ER Wilson, E Hurley, B He, BW O'Malley, Y Poitelon, L Wrabetz, ML Feltri
    Elife, 2021-09-14;10(0):.
    Species: Rat
    Sample Types: Whole Cells
    Applications: Bioassay
  2. Polyfunctional anti-human epidermal growth factor receptor 3 (anti-HER3) antibodies induced by HER3 vaccines have multiple mechanisms of antitumor activity against therapy resistant and triple negative breast cancers
    Authors: T Osada, ZC Hartman, J Wei, G Lei, AC Hobeika, WR Gwin, MA Diniz, N Spector, TM Clay, W Chen, MA Morse, HK Lyerly
    Breast Cancer Res., 2018-08-09;20(1):90.
    Species: Human
    Sample Types: Whole Cells
    Applications: Bioassay
  3. Structure of the Insulin Receptor-Insulin Complex by Single Particle CryoEM analysis
    Authors: G Scapin, VP Dandey, Z Zhang, W Prosise, A Hruza, T Kelly, T Mayhood, C Strickland, CS Potter, B Carragher
    Nature, 2018-02-28;0(0):.
    Applications: Bioassay
  4. Uridine-5'-Triphosphate Partially Blocks Differentiation Signals and Favors a more Repair State in Cultured rat Schwann Cells
    Authors: M Palomo-Gue, JM Cosgaya, A Gella, N Casals, C Grijota-Ma
    Neuroscience, 2018-01-11;0(0):.
    Species: Rat
    Sample Types: Whole Cells
    Applications: Bioassay
  5. Identification of Anti-EGFR and Anti-ErbB3 Dual Variable Domains Immunoglobulin (DVD-Ig) Proteins with Unique Activities.
    Authors: Gu J, Yang J, Chang Q, Liu Z, Ghayur T, Gu J
    PLoS ONE, 2015-05-21;10(5):e0124135.
    Species: Human
    Sample Types: Whole Cells
    Applications: Bioassay
  6. Canine epidermal neural crest stem cells: characterization and potential as therapy candidate for a large animal model of spinal cord injury.
    Authors: Gericota B, Anderson J, Mitchell G, Borjesson D, Sturges B, Nolta J, Sieber-Blum M
    Stem Cells Transl Med, 2014-01-17;3(3):334-45.
    Species: Canine
    Sample Types: Whole Cells
    Applications: Bioassay
  7. Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors.
    Authors: Wilson TR, Fridlyand J, Yan Y, Penuel E, Burton L, Chan E, Peng J, Lin E, Wang Y, Sosman J, Ribas A, Li J, Moffat J, Sutherlin DP, Koeppen H, Merchant M, Neve R, Settleman J
    Nature, 2012-07-26;487(7408):505-9.
    Species: Human
    Sample Types: Whole Cells
    Applications: Bioassay
  8. Cellular Effects of HER3-Specific Affibody Molecules.
    Authors: Gostring L, Malm M, Hoiden-Guthenberg I, Frejd FY, Stahl S, Lofblom J, Gedda L
    PLoS ONE, 2012-06-29;7(6):e40023.
    Species: Human
    Sample Types: Buffer
    Applications: Binding Assay
  9. Sema3E-Plexin D1 signaling drives human cancer cell invasiveness and metastatic spreading in mice.
    Authors: Casazza A, Finisguerra V, Capparuccia L
    J. Clin. Invest., 2010-07-26;120(8):2684-98.
    Species: Human
    Sample Types: Whole Cells
    Applications: Bioassay
  10. An activated ErbB3/NRG1 autocrine loop supports in vivo proliferation in ovarian cancer cells.
    Authors: Sheng, Qing, Liu, Xinggang, Fleming, Eleanor, Yuan, Karen, Piao, Huiying, Chen, Jinyun, Moustafa, Zeinab, Thomas, Roman K, Greulich, Heidi, Schinzel, Anna, Zaghlul, Sara, Batt, David, Ettenberg, Seth, Meyerson, Matthew, Schoeberl, Birgit, Kung, Andrew L, Hahn, William, Drapkin, Ronny, Livingston, David M, Liu, Joyce F
    Cancer Cell, 2010-03-16;17(3):298-310.
    Species: Human
    Sample Types: Whole Cells
    Applications: Bioassay
  11. ErbB2 directly activates the exchange factor Dock7 to promote Schwann cell migration.
    Authors: Yamauchi J, Miyamoto Y, Chan JR, Tanoue A
    J. Cell Biol., 2008-04-21;181(2):351-65.
    Species: Rat
    Sample Types: Whole Cells
    Applications: Bioassay
  12. Targeting ADAM-mediated ligand cleavage to inhibit HER3 and EGFR pathways in non-small cell lung cancer.
    Authors: Zhou BB, Peyton M, He B, Liu C, Girard L, Caudler E, Lo Y, Baribaud F, Mikami I, Reguart N, Yang G, Li Y, Yao W, Vaddi K, Gazdar AF, Friedman SM, Jablons DM, Newton RC, Fridman JS, Minna JD, Scherle PA
    Cancer Cell, 2006-07-01;10(1):39-50.
    Species: Human
    Sample Types: Whole Cells
    Applications: Bioassay
  13. Identification of astrocyte-expressed factors that modulate neural stem/progenitor cell differentiation.
    Authors: Barkho BZ, Song H, Aimone JB
    Stem Cells Dev., 2006-06-01;15(3):407-21.
    Species: Rat
    Sample Types: Whole Cells
    Applications: Bioassay
  14. Neuregulin-1-beta1 enters brain and spinal cord by receptor-mediated transport.
    Authors: Kastin AJ, Akerstrom V, Pan W
    J. Neurochem., 2004-02-01;88(4):965-70.
    Species: Mouse
    Sample Types: In Vivo
    Applications: In Vivo

FAQs

No product specific FAQs exist for this product, however you may

View all Proteins and Enzyme FAQs

Reviews for Recombinant Human NRG1-beta 1/HRG1-beta 1 ECD Protein

Average Rating: 5 (Based on 4 Reviews)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%

Have you used Recombinant Human NRG1-beta 1/HRG1-beta 1 ECD Protein?

Submit a review and receive an Amazon gift card.

$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image

$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image

Submit a Review

Filter by:


Recombinant Human NRG1-beta 1/HRG1-beta 1 ECD Protein
By Anonymous on 05/24/2024
Application: CellProlif

Recombinant Human NRG1-beta 1/HRG1-beta 1 ECD Protein
By Anonymous on 10/26/2021
Application: CellProlif

Recombinant Human NRG1-beta 1/HRG1-beta 1 ECD Protein
By Anonymous on 02/02/2018
Application: CellProlif

Recombinant Human NRG1-beta 1/HRG1-beta 1 ECD Protein
By Anonymous on 07/25/2017